Oral L-citrulline and Transresveratrol supplementation study for erectile function in men with phosphodieserase 5 inhibitors: randomized, double-blind, placebo-controlled crossover pilot study.

Oral L-citrulline and Transresveratrol supplementation study for erectile function in men with phosphodieserase 5 inhibitors: randomized, double-blind, placebo-controlled crossover pilot study. - L-citrulline and Transresveratrol supplementation study for erectile function.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028695

Enrollment

Registered

2017-08-18

Start date

2015-04-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Dysfunction

Interventions

Oral L-citrulline and Transresveratrol 4-week supplementation Oral placebo 4-week

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Score below 16 of Sexual Health Inventory for Men, despite on-demand use of PDE5i

Exclusion criteria

Exclusion criteria: Contraindication for PDE5i Without nerve sparing, radical prostatectomy

Design outcomes

Primary

Measure	Time frame
Sexual Health Inventory for Men	—

Secondary

Measure	Time frame
Erection Hardness Score Aging Male Scale (Sexual Domain)	—

Countries

Japan

Contacts

Public ContactMasato Shirai

Juntendo University Urayasu Hospital Department of Urology

masatos@juntendo-urayasu.jp+81-47-353-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026